In this study, we further demonstrated that the VEGFR3 inhibitor MAZ51 disrupted EphrinB2-enhanced lymphangiogenesis, thus abolishing the cardioprotective effects of EphrinB2 on post-MI phenotypes. Here, FLT4 is linked to myocardial infarction.